JP2024518712A5 - - Google Patents
Info
- Publication number
- JP2024518712A5 JP2024518712A5 JP2023562492A JP2023562492A JP2024518712A5 JP 2024518712 A5 JP2024518712 A5 JP 2024518712A5 JP 2023562492 A JP2023562492 A JP 2023562492A JP 2023562492 A JP2023562492 A JP 2023562492A JP 2024518712 A5 JP2024518712 A5 JP 2024518712A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- approximately
- patient
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163173219P | 2021-04-09 | 2021-04-09 | |
| US63/173,219 | 2021-04-09 | ||
| US202163252542P | 2021-10-05 | 2021-10-05 | |
| US63/252,542 | 2021-10-05 | ||
| US202263297960P | 2022-01-10 | 2022-01-10 | |
| US63/297,960 | 2022-01-10 | ||
| PCT/US2022/024087 WO2022217100A1 (en) | 2021-04-09 | 2022-04-08 | Treatment of cancer with kdm4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518712A JP2024518712A (ja) | 2024-05-02 |
| JP2024518712A5 true JP2024518712A5 (enExample) | 2025-04-16 |
Family
ID=83545127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562492A Pending JP2024518712A (ja) | 2021-04-09 | 2022-04-08 | Ｋｄｍ４阻害剤による癌の処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250025451A1 (enExample) |
| EP (1) | EP4319748A4 (enExample) |
| JP (1) | JP2024518712A (enExample) |
| AU (1) | AU2022254741A1 (enExample) |
| CA (1) | CA3214399A1 (enExample) |
| WO (1) | WO2022217100A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2991090T3 (es) | 2017-03-30 | 2024-12-02 | Univ Freiburg Albert Ludwigs | Inhibidores de KDM4 |
| JP2025532101A (ja) * | 2022-09-21 | 2025-09-29 | セルジーン コーポレーション | ３－（｛［（４ｒ）－７－｛メチル［４－（プロパン－２－イル）フェニル］アミノ｝－３，４－ジヒドロ－２ｈ－１－ベンゾピラン－４－イル］メチル｝アミノ）ピリジン－４－カルボン酸のｌ－リジン塩、ヒストンデメチラーゼ阻害剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0307643D0 (en) * | 2003-04-02 | 2003-05-07 | Cyclacel Ltd | Markers |
| BR112015022391B1 (pt) * | 2013-03-12 | 2021-12-21 | Abbvie Inc | Compostos inibidores do domínio bromo tetracíclico, composição farmacêutica que compreende os referidos compostos e usos terapêuticos dos mesmos |
| US20160113911A1 (en) * | 2013-06-06 | 2016-04-28 | The General Hospital Corporation | Methods and compositions for the treatment of cancer |
| CN106660982B (zh) * | 2014-06-25 | 2020-09-08 | 赛尔基因昆蒂赛尔研究公司 | 组蛋白脱甲基酶抑制剂 |
| WO2018102736A1 (en) * | 2016-12-01 | 2018-06-07 | The General Hospital Corporation | Methods for the treatment of cancer |
| ES2991090T3 (es) * | 2017-03-30 | 2024-12-02 | Univ Freiburg Albert Ludwigs | Inhibidores de KDM4 |
| WO2018222831A1 (en) * | 2017-05-31 | 2018-12-06 | The Children's Medical Center Corporation | TARGETING LYSINE DEMETHYLASES (KDMs) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA |
| WO2019083594A1 (en) * | 2017-08-21 | 2019-05-02 | The General Hospital Corporation | COMPOSITIONS AND METHODS FOR CLASSIFYING TUMORS WITH INSTABILITY OF MICROSATELLITES |
| UY38349A (es) * | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
| AU2022331536A1 (en) * | 2021-08-18 | 2024-02-22 | Celgene Corporation | Process for preparing histone demethylase inhibitors |
-
2022
- 2022-04-08 US US18/554,283 patent/US20250025451A1/en active Pending
- 2022-04-08 JP JP2023562492A patent/JP2024518712A/ja active Pending
- 2022-04-08 EP EP22785559.0A patent/EP4319748A4/en active Pending
- 2022-04-08 CA CA3214399A patent/CA3214399A1/en active Pending
- 2022-04-08 AU AU2022254741A patent/AU2022254741A1/en active Pending
- 2022-04-08 WO PCT/US2022/024087 patent/WO2022217100A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges | |
| Zheng et al. | Lysine demethylase 5B (KDM5B): a potential anti-cancer drug target | |
| WO2024088273A1 (zh) | 一种萘酰胺化合物治疗kras突变相关疾病的用途 | |
| JP2023512039A5 (enExample) | ||
| JP2019533670A5 (enExample) | ||
| Madura et al. | Mucin-hypersecreting intraductal neoplasms of the pancreas: a precursor to cystic pancreatic malignancies | |
| CN115624550B (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| JP2024528039A5 (enExample) | ||
| JP7422084B2 (ja) | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 | |
| WO2017200016A1 (ja) | Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬 | |
| KR20190111939A (ko) | 디아릴 거대환형 화합물을 수반하는 병용 요법 | |
| JP2022523214A5 (enExample) | ||
| JP2024527109A5 (enExample) | ||
| JP2019506392A5 (enExample) | ||
| CN104582706A (zh) | 辅助癌症治疗的方法 | |
| CN101332301A (zh) | 一种抗肿瘤组合物及其应用 | |
| JPWO2022270524A5 (enExample) | ||
| JP2022527499A5 (enExample) | ||
| TW200934494A (en) | Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer | |
| EP2710038B1 (en) | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER | |
| US20210023211A1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant | |
| TW202120085A (zh) | 抗ccr4抗體抵抗性之癌症的治療劑 | |
| CN101175495B (zh) | 抗癌化合物的组合 | |
| JP2022527702A (ja) | 小細胞肺がんの治療におけるキアウラニブの使用 | |
| CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 |